Key result
Ticagrelor administered at the time of thrombolysis for STEMI showed no significant difference in post-PCI corrected TIMI frame count compared to clopidogrel (28.33 vs 24.33; p=0.10).
Why the study?
Does ticagrelor improve post-PCI corrected TIMI frame count in STEMI patients treated with thrombolysis compared to clopidogrel?
Does ticagrelor improve post-PCI corrected TIMI frame count in STEMI patients treated with thrombolysis compared to clopidogrel?
Absolute Event Rate: 28.33% vs 24.33%
p-value: p=0.10
In STEMI patients treated with thrombolysis, ticagrelor did not significantly improve microvascular integrity compared to clopidogrel but was associated with higher rates of minor bleeding.
Primary percutaneous coronary intervention (PPCI) has been the preferred reperfusion strategy for patients with ST-elevation myocardial infarction (STEMI). However, in 2020, intravenous thrombolysis still remains a viable option for reperfusion. In European countries, long transportation time to PPCI has been the main indication for thrombolysis. Current clinical practice guidelines highlight the importance of the time interval from the first medical contact to the catheterisation laboratory admission1. If this is more than 120 minutes, a thrombolytic agent has to be administered first, followed by transport to the nearest catheterisation laboratory. Invasive assessment of the coronary arteries should be performed within 2-24 hours ...
No takes yet. Share an insight, caveat, or question.
Petr Kala (2021) conducted an editorial in ST-elevation myocardial infarction (STEMI) (n=335). Ticagrelor vs. Clopidogrel was evaluated on Post-PCI corrected TIMI frame count (CTFC) (p=0.10). Ticagrelor administered at the time of thrombolysis for STEMI showed no significant difference in post-PCI corrected TIMI frame count compared to clopidogrel (28.33 vs 24.33; p=0.10).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: